003090.KS
Daewoong Co., Ltd.
KSC · Healthcare · Drug Manufacturers - General · KR
KRW 17,200.00
−1.43%Year over year
Reported trailing growth
- Revenue
- +4.6%
- EBITDA
- +24.0%
- EBIT
- -23.0%
- EPS
- +132.2%
- Free cash flow
- -13.2%
- Operating cash flow
- +22.0%
Forward estimates
Based on analyst estimates
- Revenue
- -13.8%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +6.8%
- EBITDA
- +15.2%
- EBIT
- +7.9%
- Net income
- +19.5%
- EPS
- +20.2%
- Free cash flow
- +78.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026